Breaking Up is Hard to Do: When to Leave Your CRO for Optimized Pharmacovigilance

It’s been an intense year for innovation in the life sciences industry. New technologies, including artificial intelligence, are flooding the market; and the industry’s rapid growth is spotlighting the global need to bring pharma’s pharmacovigilance practices up to speed across emerging and large-scale companies.

Currently, almost 400,000 clinical studies are happening globally, according to the U.S. National Library of Medicine. Most will take an average of six to seven years to complete, and this is just the
beginning for safety data monitoring. Executing superior pharmacovigilance practices from clinical
trials throughout the product life cycle is both complicated and costly, which is exactly why 60% of manufacturers decide against independently managing their pharmacovigilance needs and extensive safety data. Too often, pharmacovigilance is further complicated for manufacturers with siloed commercial services and disjointed datasets.